Study of Olverembatinib (HQP1351) in Patients With CP-CML

NCT06423911 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

285

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myeloid Leukemia
CML
CML, Chronic Phase

Interventions

DRUG: olverembatinib
DRUG: Bosutinib

Sponsor

Ascentage Pharma Group Inc.